New cell-penetrating peptide delivers HPV E6 inhibitor into cervical cancer cells

Scientists in Italy and China have engineered a designer molecule that slips into cervical cancer cells and disarms the engine that keeps them alive. The new compound, described in the Journal of Experimental & Clinical Cancer Research, is a cell-penetrating peptide fused to a short protein fragment that blocks the E6 oncoprotein of human papillomavirus, the viral culprit behind nearly all cases of cervical cancer. In laboratory tests on HPV-positive cervical cancer cell lines, the fused peptide crossed cell membranes with high efficiency, restored the activity of p53 — a critical tumor-suppressor protein that the virus normally destroys — and halted cancer cell proliferation in a dose- and time-dependent manner. The work, led by researchers at the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples, together with collaborators at the Institute of Biostructures and Bioimaging of the National Research Council of Italy, Fudan University in Shanghai, and other institutions, offers a promising proof of concept for a therapeutic strategy that has long eluded researchers: directly targeting the viral proteins that drive HPV-associated malignancies.

The biological problem the team set out to solve is deceptively simple in outline and formidable in practice. High-risk HPV types, chiefly HPV16 and HPV18, cause cancer not by killing cells but by hijacking them. Two viral oncoproteins, E6 and E7, reprogram infected cells so that they proliferate uncontrollably and evade the built-in safeguards of normal biology. E6 performs perhaps the most damaging act of sabotage: it binds a cellular enzyme called E6AP, a ubiquitin ligase, and co-opts it into attaching molecular tags to p53, marking the tumor suppressor for destruction by the proteasome, the cell’s protein-disposal machinery. With p53 eliminated, cells carrying damaged DNA continue to divide instead of either repairing the damage or self-destructing through apoptosis. Restoring p53 in HPV-positive cancer cells is therefore widely regarded as one of the most attractive therapeutic goals in this disease, because the tumor’s survival depends on continuously suppressing a pathway that remains otherwise intact.

Earlier work had identified a remarkably short weapon against this machinery: a 15-amino-acid peptide, dubbed pep11, that physically disrupts the complex between HPV16 E6 and E6AP. By wedging into the interaction, pep11 prevents E6 from dragging p53 to its doom, allowing p53 levels to recover and triggering programmed cell death in HPV16-positive cancer cells. But pep11 had serious practical limitations as a drug candidate. Peptides of this size are generally poor at crossing the lipid membranes that surround cells, they tend to be poorly soluble in aqueous environments such as blood and culture medium, and they are vulnerable to rapid degradation. Without a delivery system, a peptide like pep11 simply cannot reach its intracellular target in sufficient quantities to be pharmacologically useful.

To overcome these barriers, the research team took the approach of fusing pep11 to a short cell-penetrating peptide, or CPP — a class of amino-acid sequences known for their ability to ferry attached cargo across cellular membranes. The resulting hybrid molecule, named CPP-pep11, was synthesized using Boc chemistry, a classical solid-phase peptide synthesis technique based on tert-butyloxycarbonyl protecting groups, carried out with expert technical assistance at the Institute of Human Virology of the University of Maryland School of Medicine. The synthesis strategy allowed the investigators to build the peptide chain amino acid by amino acid on a solid resin, cleave the finished product, and purify it by reverse-phase high-performance liquid chromatography, with its identity and purity confirmed by electrospray ionization mass spectrometry.

A key question was whether attaching the cell-penetrating sequence would ruin the very thing that made pep11 valuable: its ability to bind E6. To explore this, the team used AlphaFold2, the artificial intelligence protein-structure prediction system, to model the interactions of CPP-pep11 with both HPV16 E6 and HPV18 E6. The modeling suggested that the fused peptide can indeed interact with both oncoproteins, with a more stable predicted binding to HPV16 E6. This was an encouraging sign, because it implied that the fusion construct might retain — and potentially broaden — the antiviral activity of the original pep11 across the two high-risk HPV types most commonly found in cervical tumors. In parallel, the researchers probed the physical behavior of the peptide in solution. At a concentration of 20 micromolar, CPP-pep11 dissolved readily in water, resolving one of pep11’s key formulation problems. Nuclear magnetic resonance spectroscopy, performed with access to facilities at the University of Campania Luigi Vanvitelli, revealed that the peptide predominantly adopts a disordered, flexible conformation in solution — a characteristic common among peptides that fold upon binding their targets and not necessarily an impediment to function.

With the molecule synthesized, characterized and computationally vetted, the team moved to cell-based experiments using two well-established cervical cancer cell lines: SiHa cells, which carry HPV16, and C4-I cells, which harbor HPV18. The cells were treated with CPP-pep11 across a concentration range of 0.5 to 20 micromolar for periods of 24 to 72 hours. The first question was delivery. Using confocal microscopy and differential cell fractionation, the researchers tracked where the peptide went after it was added to the culture. The results were striking: CPP-pep11 efficiently penetrated the membranes of both cell lines, and its intracellular distribution depended on dose. At lower concentrations, from 0.5 to 5 micromolar, the peptide accumulated mainly in the cytoplasm, the compartment where E6 and E6AP carry out their destructive partnership. At higher concentrations, 10 to 20 micromolar, the peptide was also detected in the nucleus, the very compartment where p53 acts once it is rescued from degradation. For a molecule intended to interfere with a cytoplasmic protein-protein interaction and then allow a nuclear tumor suppressor to resume its work, this pattern of localization is close to ideal.

The therapeutic effects followed. Measured with the xCELLigence real-time cell analysis system, which tracks cell proliferation continuously and label-free by monitoring electrical impedance across the bottom of the culture vessel, CPP-pep11 inhibited the growth of both SiHa and C4-I cells in a manner that increased with both dose and exposure time. Colony formation assays, a stringent test of a cell’s ability to survive and reproduce over many generations, showed a significant reduction in the clonogenic capacity of treated cells, indicating that the peptide does not merely slow growth transiently but undermines the long-term reproductive fitness of the cancer cell population. Cytotoxicity assays corroborated the loss of viability, and Western blotting delivered the mechanistic payoff: p53 protein levels were restored at 48 and 72 hours after treatment, a result consistent with the peptide’s proposed mechanism of action — the disruption of E6-mediated p53 degradation. When the destruction complex is blocked, p53 accumulates, and a cell with functional p53 typically responds by arresting its division cycle or initiating apoptosis.

What makes this study notable in the broader landscape of HPV-targeted cancer therapy is its directness. Most current treatments for cervical cancer — surgery, radiotherapy, chemotherapy and, more recently, immunotherapy — act indirectly, damaging or detecting tumor cells rather than correcting the specific molecular lesion that defines them. Small-molecule inhibitors of E6 have been pursued for years, but the E6/E6AP interface is a large, shallow protein-protein contact surface of the kind that small molecules struggle to engage effectively. Peptides, by contrast, can be designed to mimic the very segments of protein that mediate such contacts, occupying the interface with high specificity. The obstacle has always been delivery, and that is precisely the obstacle the CPP fusion was designed to clear. By combining a targeting peptide with a delivery peptide in a single, water-soluble, synthetically accessible molecule, the team has produced a construct that addresses the two great weaknesses of peptide therapeutics — membrane permeability and solubility — in one step.

The path from cell culture to clinic remains long, and the authors are careful to frame CPP-pep11 as a molecule with therapeutic potential rather than an approved drug. Peptide drugs face challenges of stability in the bloodstream, immunogenicity, and the need to reach tumor tissue in vivo, and results in two-dimensional cell cultures do not always translate to the far more complex environment of a human tumor. Nevertheless, the study demonstrates each critical link in the chain of evidence: the peptide binds its predicted targets according to structural modeling, enters target cells efficiently, reaches the relevant subcellular compartments, restores the p53 pathway as its mechanism predicts, and suppresses the growth and clonogenic survival of HPV-positive cancer cells from both major high-risk HPV types. The inclusion of HPV18-positive C4-I cells is particularly significant, since it suggests the strategy is not narrow in its applicability but could extend across the spectrum of HPV-driven malignancies, which also include a substantial fraction of anal, oropharyngeal, vulvar, vaginal and penile cancers.

The work also exemplifies a modern, multidisciplinary pipeline for early-stage drug development, combining artificial intelligence structure prediction, classical solution-phase biophysics, advanced peptide chemistry and real-time cellular phenotyping. The research was supported by the Italian Ministry of Health and the Italian Association for Cancer Research, and the resulting article, published as open access, allows the wider community to scrutinize and build upon the findings. If subsequent studies — in three-dimensional tumor models, in animal systems and eventually in clinical trials — confirm that CPP-pep11 and its successors can safely restore p53 in HPV-positive tumors within the body, the strategy could open a genuinely targeted chapter in the treatment of virus-driven cancers, one in which therapy corrects the specific molecular crime committed by the virus rather than poisoning the cell that harbors it.